Little Green Pharma Valuation Multiples

Discover revenue and EBITDA valuation multiples for Little Green Pharma and similar public comparables like WM Tech, Planet 13, MariMed, iAnthus Capital Holdings and more.

Little Green Pharma Overview

About Little Green Pharma

Little Green Pharma Ltd is engaged in the vertically integrated medicinal cannabis business. The business activities of the company include cultivation, production, research and development, manufacturing, and distribution of medicinal cannabis products. The company's two key types of products available at Little Green Pharma are oils (which are ingested) and flowers (which are usually inhaled through vaporizing). It offers LGP-branded medicinal cannabis oil products in the Australian and European markets.


Founded

2016

HQ

Australia

Employees

N/A

Financials (LTM)

Revenue: $30M
Net Income: ($1M)

EV

$41M

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Little Green Pharma Financials

Little Green Pharma reported last 12-month revenue of $30M.

In the same LTM period, Little Green Pharma generated had net loss of ($1M).


Little Green Pharma P&L

In the most recent fiscal year, Little Green Pharma reported revenue of $30M and EBITDA of $2M.

Little Green Pharma is unprofitable as of last fiscal year, with gross margin of 69%, EBITDA margin of 6%, and net margin of (3%).

See analyst estimates for Little Green Pharma
LTMLast FY202320242025202620272028
Revenue$30M$30M$17M$24M$28M
Gross Profit-$21M$9M$15M$20M
Gross Margin-69%53%65%71%
EBITDA-$2M($3M)($1M)$1M
EBITDA Margin-6%(19%)(5%)5%
EBIT Margin-5%(52%)(17%)2%
Net Profit($1M)($973K)($6M)$314K($156K)
Net Margin(3%)(3%)(35%)1%(1%)
Net Debt-$1M---

Financial data powered by Morningstar, Inc.

Little Green Pharma Stock Performance

Little Green Pharma has current market cap of $39M, and enterprise value of $41M.


Little Green Pharma's stock price is $0.05.

Little Green Pharma share price increased by 13.6% in the last 30 days.

See more trading valuation data for Little Green Pharma
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$41M$39M0.4%13.6%--$-0.00

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Little Green Pharma Valuation Multiples

Little Green Pharma trades at 1.4x EV/Revenue multiple, and 22.0x EV/EBITDA.

See NTM and 2027E valuation multiples for Little Green Pharma

Little Green Pharma Financial Valuation Multiples

As of July 2, 2026, Little Green Pharma has market cap of $39M and EV of $41M.

Little Green Pharma has a P/E ratio of (38.8x).

LTMLast FY202320242025202620272028
EV/Revenue1.4x1.4x2.5x1.8x1.5x
EV/EBITDA-22.0x(13.3x)(35.7x)32.3x
EV/EBIT-28.2x(4.8x)(10.5x)84.9x
EV/Gross Profit-2.0x4.7x2.7x2.1x
P/E(38.8x)(40.2x)(6.7x)124.4xn/m
EV/FCF-(62.3x)(15.0x)(38.0x)(52.9x)

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Little Green Pharma Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Little Green Pharma Margins & Growth Rates

In the most recent fiscal year, Little Green Pharma reported gross margin of 69%, EBITDA margin of 6%, and net margin of (3%).

See estimated margins and future growth rates for Little Green Pharma

Little Green Pharma Margins

Last FY202420252026202720282029
Gross Margin69%65%71%71%
EBITDA Margin6%(5%)5%6%
EBIT Margin5%(17%)2%5%
Net Margin(3%)1%(1%)(3%)
FCF Margin(2%)(5%)(3%)(2%)

Little Green Pharma Growth Rates

23/2424/2525/2626/2727/2828/29
Revenue Growth41%21%3%
Gross Profit Growth73%30%4%
EBITDA Growth(63%)(211%)47%
EBIT Growth(54%)(112%)201%
Net Profit Growth(105%)(149%)526%
FCF Growth(61%)(28%)(15%)

Data powered by FactSet, Inc. and Morningstar, Inc.

Little Green Pharma Operational KPIs

Little Green Pharma's Rule of 40 is 10% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Little Green Pharma's Rule of X is 15% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Access forward-looking KPIs for Little Green Pharma
Last FY202320242025202620272028
Rule of 4010%---
Bessemer Rule of X15%---
S&M Expenses to Revenue15%32%23%17%
G&A Expenses to Revenue34%17%36%36%
R&D Expenses to Revenue0%26%5%0%
Opex to Revenue64%105%82%69%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Little Green Pharma Competitors

Little Green Pharma competitors include WM Tech, Planet 13, MariMed, iAnthus Capital Holdings, Peak Processing, HYTN Innovations, Vitura Health, Ispire Technology, SynBiotic and Humanoid Global Holdings.

Most Little Green Pharma public comparables operate across Cannabis, CannaTech and ViceTech.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
WM Tech0.1x0.1x0.3x0.4x
Planet 130.9x1.0x(9.4x)(15.5x)
MariMed0.7x0.7x6.6x6.6x
iAnthus Capital Holdings1.7x-13.9x-
Peak Processing1.9x-(9.4x)-
HYTN Innovations10.7x-(15.5x)-
Vitura Health0.2x-3.3x-
Ispire Technology0.4x0.6x(1.6x)84.5x

This data is available for Pro users. Sign up to see all Little Green Pharma competitors and their valuation data.

Start Free Trial

Little Green Pharma VC Funding History

Before going public, Little Green Pharma raised $8M in total equity funding, across 2 rounds.


Little Green Pharma Funding Rounds

DateStageInvestorsRaisedValuationRev. MultipleDeal Summary
Jul-19Series A-$6M-Little Green Pharma raised A$9 million in a pre-IPO convertible note fundraising in July 2019, with the notes subsequently converting into shares upon the company's ASX listing in February 2020. The company operated a GMP-compliant indoor cultivation facility in South-West Western Australia producing medicinal cannabis oil, flower, and vaporiser products for the Australian market. For the financial year ended 30 June 2020 (the closest audited reporting period to the July 2019 fundraising), Little Green Pharma generated revenue of more than A$2.2 million from the sale of over 14,860 bottles of medicinal cannabis product, compared to A$1,676 bottles in the prior year. The company achieved a gross margin of 52% in FY2020, up from 41% in the previous year, supported by increasing scale and operating efficiencies, and had more than 4,560 patients prescribed its products by the end of the year with over 315 healthcare professionals recommending its offerings.
Oct-17Seed-$2M--

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Little Green Pharma

When was Little Green Pharma founded?Little Green Pharma was founded in 2016.
Where is Little Green Pharma headquartered?Little Green Pharma is headquartered in Australia.
Is Little Green Pharma publicly listed?Yes, Little Green Pharma is a public company listed on Australian Securities Exchange.
What is the stock symbol of Little Green Pharma?Little Green Pharma trades under LGP ticker.
When did Little Green Pharma go public?Little Green Pharma went public in 2020.
Who are competitors of Little Green Pharma?Little Green Pharma main competitors include WM Tech, Planet 13, MariMed, iAnthus Capital Holdings, Peak Processing, HYTN Innovations, Vitura Health, Ispire Technology, SynBiotic, Humanoid Global Holdings.
What is the current market cap of Little Green Pharma?Little Green Pharma's current market cap is $39M.
What is the current revenue of Little Green Pharma?Little Green Pharma's last 12 months revenue is $30M.
What is the current EV/Revenue multiple of Little Green Pharma?Current revenue multiple of Little Green Pharma is 1.4x.
Is Little Green Pharma profitable?No, Little Green Pharma is not profitable.
What is the current net income of Little Green Pharma?Little Green Pharma's last 12 months net income is ($1M).
How many companies Little Green Pharma has acquired to date?Little Green Pharma hasn't acquired any companies yet (or none have been disclosed publicly).
In how many companies Little Green Pharma has invested to date?Little Green Pharma hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to Little Green Pharma

Lists including Little Green Pharma

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial